Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

MIB-725

Source date not recordedAnalyse record ↗

Next-generation investigational NAD+ precursor in early clinical safety and bioavailability testing.

Modality
oral next-generation NAD+ precursor
Availability (US)
Phase 1a safety and bioavailability testing; initial dosing was announced April 22, 2025
Biomarkers
safety, tolerability, pharmacokinetics, and bioavailability
Hallmark targeted
mitochondrial dysfunction, altered nutrient sensing, NAD+ depletion
Kind
investigational drug
Clinical trials
Company-reported Phase 1a safety and bioavailability study initiated in 2025; no ClinicalTrials.gov identifier is stated on the official company pages reviewed